Buy Roxicodone 30 mg



Buy Roxicodone 30 mg tablets in the United Kingdom and Europe from our online pharmacy with fast worldwide shipping! The greatest place to get OxyContin is right here!

Product Description

Online Purchase of Roxicodone 30mg Pills

ROXICODONE (oxycodone HCl) tablets are intended for the treatment of moderate to severe pain that requires an opioid analgesic and for which non-opioid alternatives are ineffective.

Use Restrictions

Due to the dangers of opioid addiction, abuse, and misuse, even at authorized doses, reserve ROXICODONE for patients who do not respond to alternative treatment choices (e.g., non-opioid analgesics or opioid combination products):

Have not been tolerated and are unlikely to be permitted
Have failed to administer appropriate analgesia or are not likely to administer adequate analgesia

This material is meant for healthcare professionals in the United States of America only.
Complete prescription information for the United States, including a boxed warning.

Guide to Medication


  • WARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; INTERACTION WITH CYTOCHROME P450 3A4; and RISKS FROM CONCOMITANT USE WITH BENSubstance Abuse, Abuse, and MisuseROXICODONE exposes patients and other users to the dangers of opioid addiction, abuse, and misuse, all of which can result in death from overdose. Prior to providing ROXICODONE, assess each patient’s risk and monitor all patients periodically for the development of certain behaviors and conditions.

    Risk Assessment and Mitigation Strategy for Opioid Analgesics (REMS)

    The Food and Drug Administration (FDA) requires a REMS for opioid analgesics to verify that the benefits outweigh the dangers of addiction, abuse, and misuse. Pharmaceutical companies that have approved opioid analgesic products are required to make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged to: • complete a REMS-compliant education program; • counsel patients and/or caregivers on the safe use, serious risks, storage, and disposal of these products with each prescription; • emphasize to patients and caregivers the importance of reading the Medication Guide each time it is provided by their pharmacist; and • consider additional tools to improve patient, household, and community safety.

    Life-Threatening Respiratory Depression

    ROXICODONE may cause serious, life-threatening, or deadly respiratory depression. Keep an eye out for respiratory depression, especially when starting ROXICODONE or increasing the dose.

    Consumption by Accident

    Accidental ROXICODONE ingestion, particularly by youngsters, can result in a lethal ROXICODONE overdose.

    Syndrome of Neonatal Opioid Withdrawal

    Prolonged use of ROXICODONE during pregnancy can result in newborn opioid withdrawal syndrome, which can be fatal if not diagnosed and treated promptly, and needs therapy according to neonatology-specific procedures. If prolonged opioid use is necessary in a pregnant woman, inform her about the danger of neonatal opioid withdrawal syndrome and ensure that proper therapy is available.

    Interaction with Cytochrome P450 3A4

    Concurrent usage of ROXICODONE and all cytochrome P450 3A4 inhibitors may result in an increase in plasma oxycodone concentrations, which may exacerbate or prolong unpleasant responses and may result in potentially deadly respiratory depression. Additionally, stopping a concurrently utilized cytochrome P450 3A4 inducer may result in a rise in the plasma levels of oxycodone. Patients receiving ROXICODONE and any CYP3A4 inhibitor or inducer should be closely monitored.

    Consequences of Concurrent Use with Benzodiazepines or Other Central Nervous System Depressants

    Concurrent use of opioids with benzodiazepines or other CNS depressants, such as alcohol, may result in extreme drowsiness, respiratory depression, coma, or death.

    Concurrent administration of ROXICODONE with benzodiazepines or other CNS depressants should be reserved for individuals who do not respond to alternate therapeutic alternatives.
    Keep dosages and durations to a minimum.
    Maintain an eye out for signs and symptoms of respiratory depression and sedation in patients.



ROXICODONE is contraindicated in patients with:

  • Significant respiratory depression
  • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
  • Known or suspected gastrointestinal obstruction, including paralytic ileus
  • Known hypersensitivity to oxycodone


  • ROXICODONE contains oxycodone, a Schedule II controlled substance. As an opioid, ROXICODONE exposes users to the risks of addiction, abuse, and misuse.
  • Assess each patient’s risk for opioid addiction, abuse, or misuse prior to prescribing ROXICODONE, and monitor all patients receiving ROXICODONE for the development of these behaviors and conditions.
  • To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers.
  • Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Patients with chronic pulmonary disease, elderly, cachectic, or debilitated patients may be at increased risk. Monitor closely, especially during initiation and titration.
  • Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion.
  • Accidental ingestion of even one dose of ROXICODONE, especially by children, can result in respiratory depression and death due to an overdose of ROXICODONE. Instruct patients to take steps to store ROXICODONE securely. Expired, unwanted, or unused ROXICODONE should be disposed of by flushing the unused medication down the toilet if a drug take-back option is not readily available.
  • Neonatal opioid withdrawal syndrome (NOWS) may occur following prolonged use of opioids during pregnancy. Observe newborns for signs of NOWS and manage accordingly; NOWS may be life-threatening if not recognized and treated in neonates.
  • When using CYP3A4 inhibitors or discontinuing CYP3A4 inducers in ROXICODONE -treated patients, monitor patients closely at frequent intervals and consider dosage reduction of ROXICODONE until stable drug effects are achieved. When using ROXICODONE with CYP3A4 inducers or discontinuing CYP3A4 inhibitors, monitor patients closely at frequent intervals and consider increasing the opioid dosage if needed to maintain adequate analgesia or if symptoms of opioid withdrawal occur.
  • Profound sedation, respiratory depression, coma, and death may result from the concomitant use of ROXICODONE with benzodiazepines or other CNS depressants (including alcohol and illicit drugs).
  • Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. If adrenal insufficiency is diagnosed, treat with physiologic replacement of corticosteroids and wean the patient off of the opioid until adrenal function recovers.
  • ROXICODONE may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. Monitor during initiation and/or titration of ROXICODONE. Avoid use in patients with circulatory shock.
  • Use in patients with increased intracranial pressure, brain tumors, head injury, or impaired consciousness may reduce respiratory drive, and the resultant CO2 retention can further increase intracranial pressure. Use of ROXICODONE should be avoided in patients with impaired consciousness or coma.
  • ROXICODONE is contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus. The oxycodone in ROXICODONE may cause spasms of the sphincter of Oddi.
  • The oxycodone in ROXICODONE may increase the frequency of seizures in patients with seizure disorders and may increase the risk of seizures occurring in other clinical settings associated with seizures. Monitor patients with a history of seizure disorders for worsened seizure control.
  • Do not abruptly discontinue ROXICODONE in a patient physically dependent on opioids. When discontinuing ROXICODONE in a physically dependent patient, gradually taper the dosage. Rapid tapering of oxycodone in a patient physically dependent on opioids may lead to a withdrawal syndrome and return of pain.
  • Avoid the use of ROXICODONE with mixed agonist/antagonists or partial agonist analgesics due to the risk of precipitation of withdrawal symptoms.
  • Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of ROXICODONE and know how they will react to the medication.
  • Opioids could cause a rare but potentially life-threatening condition resulting from the concomitant administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome and seek medical attention right away if symptoms develop.
  • The use of ROXICODONE is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.

Effects of Roxicodone

Serious adverse reactions associated with ROXICODONE use include respiratory depression, respiratory arrest, circulatory depression, cardiac arrest, hypotension, and/or shock. The most common adverse reactions include nausea, constipation, vomiting, headache, pruritus, insomnia, dizziness, asthenia, and somnolence.

This is not a complete list of potential adverse events associated with ROXICODONE. Please see Full Prescribing Information for a complete list.



Description Blue tablets scored
Generic Name Oxycodone hydrochloride tablets USP
Dosage Strength 30 mg
Identification Code Blue tablet scored (identified 54 199) [Embossed 54 199 on one side]

roxicodone pills, buy roxicodone pills, list of round blue roxicodone pills, pills that look like roxicodone, roxicodone pills change, roxicodone pills 30, breaking time release pills roxicodone, how to be a drug dealer selling roxicodone pills, pills that contain roxicodone, codeine syrup pills roxicodone, how much are roxicodone 30mg pills in mexico, what is in the fake k 9 roxicodone pills?, 30mg roxicodone blue pills,roxicodone, oxycodone 5 mg, pink pill, m 30 pill, m 30 blue pill, k 56 pill, roxycodone, t 194 pill, percocet 30 mg, molly prices, can you take, roxy 30, oxicodona, u17 pill, oxycodone dosage

Additional Information


60 pills, 90 pills


There are no reviews yet.

Be the first to review “Buy Roxicodone 30 mg”

Global Med Pharmacy Emblem.

Visit us on social networks:

Visit us on social networks:

Copyright © 2023 Global Med Pharmacy. All rights reserved.